A Phase 1, Single-center, Open-label Pharmacokinetic, Safety and Tolerability Study of SB204 in Adolescents With Moderate to Severe Acne Vulgaris

Trial Profile

A Phase 1, Single-center, Open-label Pharmacokinetic, Safety and Tolerability Study of SB204 in Adolescents With Moderate to Severe Acne Vulgaris

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Nitric oxide (Primary)
  • Indications Acne vulgaris
  • Focus Pharmacokinetics
  • Sponsors Novan Inc
  • Most Recent Events

    • 27 Apr 2017 Results from this trial will be presented at the 76th Annual Meeting of the Society for Investigative Dermatology 2017, as per a Novan therapeutics media release.
    • 03 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
    • 03 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top